Applications of nanomedicine in breast cancer detection, imaging, and therapy

Journal of Nanoscience and Nanotechnology

Volumn 14, Issue 1, 2014, Pages 913-923

  Saadeh, Yamaan ^a   Leung, Tiffany ^a   Vyas, Arpita ^a   Chaturvedi, Lakshmi Shankar ^a   Perumal, Omathanu ^b   Vyas, Dinesh ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b SOUTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Detection; Imaging; Nanomedicine; Therapy

Indexed keywords

BREAST CANCER; BREAST CANCER DETECTION; CHEMOTHERAPEUTIC AGENTS; MINIMALLY INVASIVE; REDUCED FREQUENCY; SEMICONDUCTOR CRYSTALS; THERAPY; TREATMENT MODALITY;

CHEMOTHERAPY; DIAGNOSIS; DISEASES; DRUG DELIVERY; ERROR DETECTION; IMAGING TECHNIQUES; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; PATIENT TREATMENT; SEMICONDUCTOR QUANTUM DOTS;

MEDICAL IMAGING;

ANTINEOPLASTIC AGENT; NANOCAPSULE;

BREAST TUMOR; CHEMISTRY; FEMALE; HUMAN; METHODOLOGY; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NANOCAPSULES; NANOMEDICINE;

EID: 84893802893     PISSN: 15334880     EISSN: 15334899     Source Type: Journal    
DOI: 10.1166/jnn.2014.8755     Document Type: Review

References (101)

1. M. H. Forouzanfar, K. J. Foreman, A. M. Delossantos, R. Lozano, A. D. Lopez, C. J. Murray, and M. Naghavi, Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet 378, 9801 (2011).
2. C. DeSantis, R. Siegel, P. Bandi, and A. Jemal, Breast Cancer Statistics, 2011 CA. Cancer J. Clin. 61, 6 (2011).
3. A. S. Leong and Z. Zhuang, The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology 78, 2 (2011).
4. S. R. Grobmyer, G. Zhou, L. G. Gutwein, N. Iwakuma, P. Sharma, and S. N. Hochwald, Nanoparticle delivery for metastatic breast cancer. Nanomedicine 8, 1 (2012).
5. E. Y. K. Ng, R. U. Acharya, and J. S. Suri, Performance Evaluation in Breast Cancer: Screening, Diagnosis and Treatment, American Scientific Publishers, Los Angeles (2010).
6. A. Hellebust and R. Richards-Kortum, Advances in molecular imaging: Targeted optical contrast agents for cancer diagnostics. Nanomedicine 7, 3 (2012).
7. A. Almutairi, W. J. Akers, M. Y. Berezin, S. Achilefu, and J. M. Frechet, Monitoring the biodegradation of dendritic near-infrared nanoprobes by in vivo fluorescence imaging. Mol. Pharm. 5, 6 (2008).
8. M. A. Hahn, A. K. Singh, P. Sharma, S. C. Brown, and B. M. Moudgil, Nanoparticles as contrast agents for in-vivo bioimaging: Current status and future perspectives. Anal. Bioanal. Chem. 399, 1 (2011).
9. A. Almutairi, S. J. Guillaudeu, M. Y. Berezin, S. Achilefu, and J. M. Frechet, Biodegradable pH-sensing dendritic nanoprobes for near-infrared fluorescence lifetime and intensity imaging. J. Am. Chem. Soc. 130, 2 (2008).
10. M. V. Yezhelyev, X. Gao, Y. Xing, A. Al-Hajj, S. Nie, and R. M. O'Regan, Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 7, 8 (2006).
11. M. Yezhelyev, R. Yacoub, and R. O'Regan, Inorganic nanoparticles for predictive oncology of breast cancer. Nanomedicine 4, 1 (2009).
12. K. K. Jain, Personalised medicine for cancer: From drug development into clinical practice Expert Opin. Pharmacother. 6, 9 (2005).
13. A. G. Cuenca, H. Jiang, S. N. Hochwald, M. Delano, W. G. Cance, and S. R. Grobmyer, Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107, 3 (2006).
14. R. L. Manthe, S. P. Foy, N. Krishnamurthy, B. Sharma, and V. Labhasetwar, Tumor ablation and nanotechnology, Mol. Pharm. 7, 6 (2010).
15. A. Z. Wang, R. Langer, and O. C. Farokhzad, Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63 (2012).
16. P. Sharma, A. Singh, S. C. Brown, N. Bengtsson, G. A. Walter, S. R. Grobmyer, N. Iwakuma, S. Santra, E. W. Scott, and B. M. Moudgil, Multimodal nanoparticulate bioimaging contrast agents methods. Mol. Biol. 624 (2010).
17. S. Singh, Nanomedicine-nanoscale drugs and delivery systems. J. Nanosci. Nanotechnol. 10, 12 (2010).
18. K. K. Jain, Nanotechnology-based drug delivery for cancer. Technol. Cancer Res. Treat. 4, 4 (2005).
19. G. Batist, G. Ramakrishnan, C. S. Rao, A. Chandrasekharan, J. Gutheil, T. Guthrie, P. Shah, A. Khojasteh, M. K. Nair, K. Hoelzer, K. Tkaczuk, Y. C. Park, and L. W. Lee, Reduced cardiotoxicity and preserved antitumor efficacy of liposomeencapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 19, 5 (2001).
20. W. J. Gradishar, S. Tjulandin, N. Davidson, H. Shaw, N. Desai, P. Bhar, M. Hawkins, and J. O'Shaughnessy, Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23, 31 (2005).
21. J. W. Park, Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 4, 3 (2002).
22. X. Gao, L. Yang, J. A. Petros, F. F. Marshall, J. W. Simons, and S. Nie, In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol. 16, 1 (2005).
23. D. J. Bharali, M. Khalil, M. Gurbuz, T. M. Simone, and S. A. Mousa, Nanoparticles and cancer therapy: A concise review with emphasis on dendrimers. Int. J. Nanomed. 4 (2009).
24. R. Hardman, A toxicologic review of quantum dots: Toxicity depends on physicochemical and environmental factors. Environ. Health Perspect 114, 2 (2006).
25. S. Magnaldi, P. Cecconi, M. Skrap, C. Ricci, M. A. Cova, and R. S. Pozzi-Mucelli, Magnetic resonance in trigeminal neuralgia. La Radiologia medica 83, 6 (1992).
26. N. Banatvala and L. Doyal, Knowing when to say "no" on the student elective. Students going on electives abroad need clinical guidelines. BMJ 316, 7142 (1998).
27. S. C. Michel, T. M. Keller, J. M. Frohlich, D. Fink, R. Caduff, B. Seifert, B. Marincek, and R. A. Kubik-Huch, Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. Radiology 225, 2 (2002).
28. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365, 9472 (2005).
29. X. Q. Yang, C. Chen, C. W. Peng, J. X. Hou, S. P. Liu, C. B. Qi, Y. P. Gong, X. B. Zhu, D. W. Pang, and Y. Li, Quantum dot-based quantitative immunofluorescence detection and spectrum analysis of epidermal growth factor receptor in breast cancer tissue arrays. Int. J. Nanomed. 6 (2011).
30. S. Biesterfeld, H. L. Kraus, T. Reineke, L. Muys, A. M. Mihalcea, and C. Rudlowski, Analysis of the reliability of manual and automated immunohistochemical staining procedures. A pilot study. Anal. Quant. Cytol. Histol. 25, 2 (2003).
31. C. Chen, J. Peng, H. S. Xia, G. F. Yang, Q. S. Wu, L. D. Chen, L. B. Zeng, Z. L. Zhang, D. W. Pang, and Y. Li, Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials 30, 15 (2009).
32. I. L. Medintz, H. Mattoussi, and A. R. Clapp, Potential clinical applications of quantum dots. Int. J. Nanomed. 3, 2 (2008).
33. E. I. Galanzha, J. W. Kim, and V. P. Zharov, Nanotechnology-based molecular photoacoustic and photothermal flow cytometry platform for in-vivo detection and killing of circulating cancer stem cells. J. Biophotonics 2, 12 (2009).
34. E. I. Galanzha, E. V. Shashkov, T. Kelly, J. W. Kim, L. Yang, and V. P. Zharov, In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat. Nanotechnol. 4, 12 (2009).
35. W. E. Doering and S. Nie, Spectroscopic tags using dye-embedded nanoparticles and surface-enhanced Raman scattering. Anal. Chem. 75, 22 (2003).
36. Y. Xu, H. Lee, Y. Hu, J. Huang, S. Kim, and M. Yun, Detection and identification of breast cancer volatile organic compounds biomarkers using highly-sensitive single nanowire array on a chip. J. Biomed. Nanotechnol. 9, 7 (2013).
37. M. E. Akerman, W. C. Chan, P. Laakkonen, S. N. Bhatia, and E. Ruoslahti, Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. USA 99, 20 (2002).
38. L. Yang, X. H. Peng, Y. A. Wang, X. Wang, Z. Cao, C. Ni, P. Karna, X. Zhang, W. C. Wood, X. Gao, S. Nie, and H. Mao, Receptortargeted nanoparticles for in vivo imaging of breast cancer. Clin. Cancer Res. 15, 14 (2009).
39. M. R. Loebinger, P. G. Kyrtatos, M. Turmaine, A. N. Price, Q. Pankhurst, M. F. Lythgoe, and S. M. Janes, Magnetic resonance imaging of mesenchymal stem cells homing to pulmonary metastases using biocompatible magnetic nanoparticles. Cancer Res. 69, 23 (2009).
40. T. Reuveni, M. Motiei, Z. Romman, A. Popovtzer, and R. Popovtzer, Targeted gold nanoparticles enable molecular CT imaging of cancer: An in vivo study. Int. J. Nanomed. 6 (2011).
41. J. F. Hainfeld, M. J. O'Connor, F. A. Dilmanian, D. N. Slatkin, D. J. Adams, and H. M. Smilowitz, Micro-CT enables microlocalisation and quantification of Her2-targeted gold nanoparticles within tumour regions. Br. J. Radiol. 84, 1002 (2011).
42. EditoršEditors, Multiple profiling of human breast cancer cell lines with quantum dots.Ab conjugates. Proc. Am. Assoc. Cancer Res. (Year).
43. C. Leuschner, C. Kumar, M. Urbina, J. Zhou, W. Soboyejo, W. Hansel, and F. Hormes, The use of ligand conjugated superparamagnetic iron oxide nanoparticles (SPION) for early detection of metastases. NSTI Nanotechnol. Technical Proc. 1 (2005).
44. D. D. D'Angelo-Donovan, D. Dickson-Witmer, and N. J. Petrelli, Sentinel lymph node biopsy in breast cancer: A history and current clinical recommendations. Surg. Oncol. 21, 3 (2012).
45. J. H. Howard and K. I. Bland, Current management and treatment strategies for breast cancer. Curr. Opin. Obstet. Gynecol. 24, 1 (2012).
46. I. K. Komenaka, V. P. Bauer, F. R. Schnabel, E. Horowitz, K. A. Joseph, B. A. Ditkoff, and M. B. El-Tamer, Allergic reactions to isosulfan blue in sentinel lymph node mapping. Breast J. 11, 1 (2005).
47. S. Kim, Y. T. Lim, E. G. Soltesz, A. M. De Grand, J. Lee, A. Nakayama, J. A. Parker, T. Mihaljevic, R. G. Laurence, D. M. Dor, L. H. Cohn, M. G. Bawendi, and J. V. Frangioni, Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol. 22, 1 (2004).
48. A. Robe, E. Pic, H. P. Lassalle, L. Bezdetnaya, F. Guillemin, and F. Marchal, Quantum dots in axillary lymph node mapping: Biodistribution study in healthy mice. BMC Cancer 8, (2008).
49. D. Krag, D. Weaver, T. Ashikaga, F. Moffat, V. S. Klimberg, C. Shriver, S. Feldman, R. Kusminsky, M. Gadd, J. Kuhn, S. Harlow, and P. Beitsch, The sentinel node in breast cancer.A multicenter validation study. N. Engl. J. Med. 339, 14 (1998).
50. G. R. Mundy, Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 8 (2002).
51. P. Clezardin, Therapeutic targets for bone metastases in breast cancer. Breast Cancer Res. 13, 2 (2011).
52. A. P. Mann, T. Tanaka, A. Somasunderam, X. Liu, D. G. Gorenstein, and M. Ferrari, E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv. Mater. 23, 36 (2011).
53. V. Elazar, H. Adwan, T. Bauerle, K. Rohekar, G. Golomb, and M. R. Berger, Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. Int. J. Cancer 126, 7 (2010).
54. T. Wadasadawala, S. Gupta, V. Bagul, and N. Patil, Brain metastases from breast cancer: Management approach. J. Cancer Res. Ther. 3, 3 (2007).
55. F. M. Kievit and M. Zhang, Cancer nanotheranostics: Improving imaging and therapy by targeted delivery across biological barriers. Adv. Mater. 23, 36 (2011).
56. N. Bednarz-Knoll, C. Alix-Panabieres, and K. Pantel, Clinical relevance and biology of circulating tumor cells. Breast Cancer Res. 13, 6 (2011).
57. V. P. Zharov, E. I. Galanzha, E. V. Shashkov, N. G. Khlebtsov, and V. V. Tuchin, In vivo photoacoustic flow cytometry for monitoring of circulating single cancer cells and contrast agent. Opt. Lett. 31, 24 (2006).
58. E. I. Galanzha, E. V. Shashkov, P. M. Spring, J. Y. Suen, and V. P. Zharov, In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res. 69, 20 (2009).
59. A. D. Hughes and M. R. King, Nanobiotechnology for the capture and manipulation of circulating tumor cells. Rev. Nanomed. Nanobiotechnol. 4, 3 (2012).
60. M. R. Choi, K. J. Stanton-Maxey, J. K. Stanley, C. S. Levin, R. Bardhan, D. Akin, S. Badve, J. Sturgis, J. P. Robinson, R. Bashir, N. J. Halas, and S. E. Clare, A cellular trojan horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 7, 12 (2007).
61. L. C. Kennedy, A. S. Bear, J. K. Young, N. A. Lewinski, J. Kim, A. E. Foster, and R. A. Drezek, T cells enhance gold nanoparticle delivery to tumors in vivo. Nanoscale Res. Lett. 6, 1 (2011).
62. S. R. Grobmyer, D. L. Morse, B. Fletcher, L. G. Gutwein, P. Sharma, V. Krishna, S. C. Frost, B. M. Moudgil, and S. C. Brown, The promise of nanotechnology for solving clinical problems in breast cancer. J. Surg. Oncol. 103, 4 (2011).
63. Y. Liu, M. Solomon, and S. Achilefu, Perspectives and potential applications of nanomedicine in breast and prostate cancer. Med. Res. Rev. 33, 1 (2013).
64. Y. Yang and H. Wang, Perspectives of nanotechnology in minimally invasive therapy of breast cancer. J. Healthc. Eng. 4, 1 (2013).
65. S. Abbasi, A. Paul, W. Shao, and S. Prakash, Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: Preparation and in vitro assessment. J. Drug Deliv. 2012, 1 (2012).
66. N. S. Rejinold, K. Chennazhi, S. V. Nair, and R. Jayakumar, Thermo-responsive chitosan-graft-poly(N-isopropyl acrylamide) co-polymeric nanoparticles for 5-fluorouracil delivery to breast cancer cells in vitro. J. Nanopharm. Drug Delivery 1, 1 (2013).
67. T. Tanaka, P. Decuzzi, M. Cristofanilli, J. H. Sakamoto, E. Tasciotti, F. M. Robertson, and M. Ferrari, Nanotechnology for breast cancer therapy. Biomed. Microdevices 11, 1 (2009).
68. I. Cucinotto, L. Fiorillo, S. Gualtieri, M. Arbitrio, D. Ciliberto, N. Staropoli, A. Grimaldi, A. Luce, P. Tassone, M. Caraglia, and P. Tagliaferri, Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: Nanodelivery reaches prime-time? J. Drug Deliv. 2013, 1 (2013).
69. N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, A. Yang, C. Tao, T. De, B. Beals, D. Dykes, P. Noker, R. Yao, E. Labao, M. Hawkins, and P. Soon-Shiong, Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophorbased paclitaxel. Clin. Cancer Res. 12, 4 (2006).
70. C. M. Hu and L. Zhang, Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 83, 8 (2012).
71. Y. Patil, T. Sadhukha, L. Ma, and J. Panyam, Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control Release 136, 1 (2009).
72. L. L. Li, Q. Yin, J. Cheng, and Y. Lu, Polyvalent mesoporous silica nanoparticle-aptamer bioconjugates target breast cancer cells. Adv. Healthc. Mater. 1, 5 (2012).
73. A. L. Lee, Y. Wang, H. Y. Cheng, S. Pervaiz, and Y. Y. Yang, The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30, 5 (2009).
74. D. Hogemann-Savellano, E. Bos, C. Blondet, F. Sato, T. Abe, L. Josephson, R. Weissleder, J. Gaudet, D. Sgroi, P. J. Peters, and J. P. Basilion, The transferrin receptor: A potential molecular imaging marker for human cancer. Neoplasia 5, 6 (2003).
75. T. R. Daniels, E. Bernabeu, J. A. Rodriguez, S. Patel, M. Kozman, D. A. Chiappetta, E. Holler, J. Y. Ljubimova, G. Helguera, and M. L. Penichet, The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 1820, 3 (2012).
76. P. P. Ng, J. S. Dela Cruz, D. N. Sorour, J. M. Stinebaugh, S. U. Shin, D. S. Shin, S. L. Morrison, and M. L. Penichet, An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc. Natl. Acad. Sci. USA 99, 16 (2002).
77. F. Wang, X. Jiang, D. C. Yang, R. L. Elliott, and J. F. Head, Doxorubicin-gallium-transferrin conjugate overcomes multidrug resistance: Evidence for drug accumulation in the nucleus of drug resistant MCF-7/ADR cells. Anticancer Res. 20, 2A (2000).
78. Y. Zheng, B. Yu, W. Weecharangsan, L. Piao, M. Darby, Y. Mao, R. Koynova, X. Yang, H. Li, S. Xu, L. J. Lee, Y. Sugimoto, R. W. Brueggemeier, and R. J. Lee, Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7alpha-APTADD to breast cancer cells. Int. J. Pharm. 390, 2 (2010).
79. S. Acharya, F. Dilnawaz, and S. K. Sahoo, Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials 30, 29 (2009).
80. L. R. Hirsch, R. J. Stafford, J. A. Bankson, S. R. Sershen, B. Rivera, R. E. Price, J. D. Hazle, N. J. Halas, and J. L. West, Nanoshellmediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. USA 100, 23 (2003).
81. F. Takeshita, Y. Minakuchi, S. Nagahara, K. Honma, H. Sasaki, K. Hirai, T. Teratani, N. Namatame, Y. Yamamoto, K. Hanai, T. Kato, A. Sano, and T. Ochiya, Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. USA 102, 34 (2005).
82. M. Kumar, M. Yigit, G. Dai, A. Moore, and Z. Medarova, Imageguided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 70, 19 (2010).
83. J. Chia, N. Kusuma, R. Anderson, B. Parker, B. Bidwell, L. Zamurs, E. Nice, and N. Pouliot, Evidence for a role of tumorderived laminin-511 in the metastatic progression of breast cancer. Am. J. Pathol. 170, 6 (2007).
84. S. Subbaram and C. M. Dipersio, Integrin alpha3beta1 as a breast cancer target. Expert Opin. Ther. Targets 15, 10 (2011).
85. R. Sadej, H. Romanska, G. Baldwin, K. Gkirtzimanaki, V. Novitskaya, A. D. Filer, Z. Krcova, R. Kusinska, J. Ehrmann, C. D. Buckley, R. Kordek, P. Potemski, A. G. Eliopoulos, N. Lalani el, and F. Berditchevski, CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol. Cancer Res. 7, 6 (2009).
86. L. Chatzistamou, A. V. Schally, A. Nagy, P. Armatis, K. Szepeshazi, and G. Halmos, Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207. Clin. Cancer Res. 6, 10 (2000).
87. C. Duggan, T. Maguire, E. McDermott, N. O'Higgins, J. J. Fennelly, and M. J. Duffy, Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int. J. Cancer 61, 5 (1995).
88. S. Dagar, M. Sekosan, B. S. Lee, I. Rubinstein, and H. Onyuksel, VIP receptors as molecular targets of breast cancer: Implications for targeted imaging and drug delivery. J. Control Release 74, 1 (2001).
89. E. S. Krystofiak, V. Z. Matson, D. A. Steeber, and J. A. Oliver, Elimination of tumor cells using folate receptor targeting by antibody-conjugated, gold-coated magnetite nanoparticles in a murine breast cancer model. J. Nanomater. 2012, 1 (2012).
90. X. H. Peng, X. Qian, H. Mao, A. Y. Wang, Z. G. Chen, S. Nie, and D. M. Shin, Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int. J. Nanomed. 3, 3 (2008).
91. C. Braicu, C. D. Gherman, A. Irimie, and I. Berindan-Neagoe, Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells, J. Nanosci. Nanotechnol. 13, 1 (2013).
92. S. E. Singletary, B. D. Fornage, N. Sneige, M. I. Ross, R. Simmons, A. Giuliano, N. Hansen, H. M. Kuerer, L. A. Newman, F. C. Ames, G. Babiera, F. Meric, K. K. Hunt, B. Edeiken, and A. N. Mirza, Radiofrequency ablation of early-stage invasive breast tumors: An overview, Cancer J. 8, 2 (2002).
93. E. S. Singletary, Feasibility of radiofrequency ablation for primary breast cancer. Breast Cancer 10, 1 (2003).
94. C. J. Gannon, C. R. Patra, R. Bhattacharya, P. Mukherjee, and S. A. Curley, Intracellular gold nanoparticles enhance non-invasive radiofrequency thermal destruction of human gastrointestinal cancer cells. J. Nanobiotechnol. 6, 2 (2008).
95. M. S. Sabel, Cryoablation for breast cancer: No need to turn a cold shoulder. J. Surg. Oncol. 97, 6 (2008).
96. M. S. Sabel, M. A. Nehs, G. Su, K. P. Lowler, J. L. Ferrara, and A. E. Chang, Immunologic response to cryoablation of breast cancer. Breast Cancer Res. Treat. 90, 1 (2005).
97. R. J. Ablin, The use of cryosurgery for breast cancer. Arch. Surg. 133, 1 (1998).
98. J. Liu and Z. S. Deng, Nano-cryosurgery: Advances and challenges. J. Nanosci. Nanotechnol. 9, 8 (2009).
99. T. G. Ahn, B. R. Lee, E. Y. Choi, D. W. Kim, and S. J. Han, Photodynamic therapy for breast cancer in a BALB/c mouse model. J. Gynecol. Oncol. 23, 2 (2012).
100. M. K. Oo, X. Yang, H. Du, and H. Wang, 5-aminolevulinic acidconjugated gold nanoparticles for photodynamic therapy of cancer. Nanomedicine 3, 6 (2008).
101. L. Zhao, M. Huo, J. Liu, Z. Yao, D. Li, Z. Zhao, and J. Tang, In vitro investigation on the magnetic thermochemotherapy mediated by magnetic nanoparticles combined with methotrexate for breast cancer treatment. J. Nanosci. Nanotechnol. 13, 2 (2013).